MS and COVID-19

• Research type

  Research Study

• Full title

  Towards understanding the risk of SARS-CoV-2 infection and immune response to COVID-19 vaccines in individuals with immune-mediated conditions

• IRAS ID

  293478

• Contact name

  Olga Ciccarelli

• Contact email

  o.ciccarelli@ucl.ac.uk

• Sponsor organisation

  UCL

• Clinicaltrials.gov Identifier

  tbc, UCL Data Protection

• Duration of Study in the UK

  1 years, 6 months, 0 days

• Research summary

  In this study we will assess how COVID-19 vaccines affect patients with immune-mediated conditions, using MS as a model. We will seek to determine whether these vaccines are safe or could potentially induce an immune response that can activate the disease in people with MS. Furthermore, there is an urgent need to better understand the effects of immunosuppressive treatments (such as DMTs) on COVID-19 vaccine response and whether this is dependent on patient-specific factors (demographics, co-morbidities etc).

• REC name

  East Midlands - Nottingham 2 Research Ethics Committee

• REC reference

  21/EM/0153

• Date of REC Opinion

  2 Jul 2021

• REC opinion

  Further Information Favourable Opinion